Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy.

ABSTRACT: Diabetes mellitus is a chronic metabolic disease that occurs when the pancreas is not producing enough insulin or when the insulin that it does produce is not able to be used effectively in the body. This results in hyperglycemia and if the blood sugars are not controlled, then it can lead to serious damage of various body systems, especially the nerves and the blood vessels. Uncontrolled diabetes is a major cause of kidney failure, heart attacks, stroke and amputation. One of the most devastating complications for patients is diabetic retinopathy (DR) which represents the leading cause of preventable vision loss in people between 20 and 65 years of age. Sodium glucose transporter 2 (SGLT2) inhibitors have been shown to reduce the risk for cardiovascular and renal events, however literatur

SUBMITTER: Matthews J 

PROVIDER: S-EPMC8891593 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature